American Medical Directors Association Foundation to Initiate Study of VeriMed Patient...

American Medical Directors Association Foundation to Initiate Study of VeriMed Patient Identification System

Study Goal to Demonstrate Improved Patient Outcomes Due to Better
Access to Important Medical Information
DELRAY BEACH, Fla.--(Business Wire)--VeriChip Corporation ("VeriChip" or the "Company") (Nasdaq:CHIP),
a provider of RFID systems for healthcare and patient-related needs,
announced today that the American Medical Directors Association (AMDA)
will initiate a study of the Company's VeriMed(TM) Patient
Identification System. The Institutional Review Board (IRB)-approved
study is expected to begin February 1.

This IRB-approved study by the AMDA Foundation responds to the
growing physician demand for the VeriMed Patient Identification
System. Upon completion of the study, the Company intends to use the
results to seek reimbursement approval from insurance companies and
the Centers for Medicare & Medicaid Services (CMS).

Scott R. Silverman, Chairman and Chief Executive Officer of
VeriChip, said, "This AMDA Foundation study is extremely important; we
believe a positive outcome will bring us one step closer to insurance
and CMS reimbursement, which we see as a turning point in the future
growth of our company."

The study is a prospective, randomized, comparative clinical study
to assess whether implementation of the VeriMed Patient Identification
System can improve patient outcomes and medical information
acquisition and documentation in transfers from long-term care
facilities, including both skilled nursing facilities and assisted
living facilities, to hospital emergency departments. The study will
involve a total of 10 facilities and 100 participants and will last
one year, or until the 100th hospitalization, whichever occurs later.

About the AMDA Foundation

The AMDA Foundation, an independent not-for-profit organization,
serves as the research arm of AMDA. The Foundation's mission is: "The
AMDA Foundation advances excellence in patient care through research
and its translation into long term care practice to support the
members and mission of the American Medical Directors Association
(AMDA)." The Foundation also takes an active role in outreach to
residents, fellows and young career physicians with an interest in
long term care. Visit the AMDA Foundation at www.amdafoundation.org.

About VeriChip

VeriChip Corporation, headquartered in Delray Beach, Florida,
develops, markets and sells radio frequency identification, or RFID,
systems used to identify, locate and protect people and assets.
VeriChip's goal is to become the leading provider of RFID systems for
people in the healthcare industry. The Company recently began
marketing its VeriMed(TM) Patient Identification System, a passive
RFID system for rapidly and accurately identifying people who arrive
in an emergency room and are unable to communicate. This system uses
the first human-implantable passive RFID microchip, the implantable
VeriChip(TM), cleared for medical use in October 2004 by the United
States Food and Drug Administration.

For more information on VeriChip, please call 1-800-970-2447, or
email info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.

Statements about the Company's future expectations, including
future revenues and earnings, and all other statements in this press
release other than historical facts are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as that term
is defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and the Company's actual results could
differ materially from expected results. The Company undertakes no
obligation to update forward-looking statements to reflect
subsequently occurring events or circumstances.

For VeriChip Corporation, Delray Beach
CEOcast
Dan Schustack, 212-732-4300
or
VeriChip Corporation
Allison Tomek, 561-805-8008
atomek@adsx.com

Copyright Business Wire 2008